KESTRA MEDICAL TECHNOLOGIES, LTD.
KMTSNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · D0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | $59.8M | $27.8M |
| Operating income | −$106.4M | −$85.1M |
| Net income | −$113.8M | −$94.1M |
| Total assets | $295.7M | $45.9M |
| Total liabilities | $90.3M | $78.2M |
| Equity | $205.4M | −$209.4M |
| EPS (diluted) | $-5.13 | $-5.07 |
| Shares out. | 51.3M | 105,808 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −177.8%
- Net margin
- −190.3%
- Return on equity
- −55.4%
- Return on assets
- −38.5%
- Return on capital (ROCE)
- −41.3%
- Liabilities / assets
- 30.5%
- Debt / equity
- 0.44×
- Book value / share
- $4.00
- Revenue growth (YoY)
- 115.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.94distress
- Accruals / assets
- −12.2%clean
- Beneish M-Score
- -1.68elevated
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.3M | 12.3 | -5.2% |
| Apr 30, 2026 | 3.5M | 13.2 | -4.7% |
| Apr 15, 2026 | 3.6M | 12.9 | +3.9% |
| Mar 31, 2026 | 3.5M | 5.8 | +24.8% |
| Mar 13, 2026 | 2.8M | 6.6 | +4.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMar 17, 2026
- Results of operationsDec 11, 2025
- Entered a material agreementDec 4, 2025
- Results of operationsDec 1, 2025
- Regulation FD disclosureNov 10, 2025
- Results of operationsSep 11, 2025
- Shareholder voteSep 4, 2025
- Results of operationsJul 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.